The estimated Net Worth of Chris M. Calcaterra is at least $39.9 million dollars as of 1 February 2021. Mr. Calcaterra owns over 60,417 units of Glaukos stock worth over $28,139,987 and over the last 9 years he sold GKOS stock worth over $9,729,457. In addition, he makes $2,048,590 as Chief Operating Officer at Glaukos.
Sign up
Mr. Calcaterra GKOS stock SEC Form 4 insiders trading
Chris has made over 12 trades of the Glaukos stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 60,417 units of GKOS stock worth $996,276 on 1 February 2021.
The largest trade he's ever made was selling 90,000 units of Glaukos stock on 5 March 2019 worth over $6,092,100. On average, Chris trades about 19,272 units every 67 days since 2015. As of 1 February 2021 he still owns at least 224,223 units of Glaukos stock.
You can see the complete history of Mr. Calcaterra stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Chris Calcaterra biography
Chris M. Calcaterra serves as Chief Operating Officer of the Company. Mr. Calcaterra served as our chief commercial officer from April 2008 until becoming our chief operating officer in February 2017. He has more than 30 years of experience in the ophthalmic medical technology industry. Prior to joining our Company, Mr. Calcaterra was senior vice president at Advanced Medical Optics, Inc. (acquired by Abbott Laboratories), and was responsible for its cataract business. Prior to that position, Mr. Calcaterra held increasingly responsible vice president positions in a variety of sales and marketing roles at Advanced Medical Optics, Inc., as well as its predecessor surgical division business at Allergan, Inc. Mr. Calcaterra has a B.S. from Miami University and an M.B.A. from Xavier University, and he was previously a board member of WaveTec Vision Systems, Inc. (acquired by Novartis).
What is the salary of Chris Calcaterra?
As the Chief Operating Officer of Glaukos, the total compensation of Chris Calcaterra at Glaukos is $2,048,590. There are 1 executives at Glaukos getting paid more, with Thomas Burns having the highest compensation of $5,716,560.
How old is Chris Calcaterra?
Chris Calcaterra is 59, he's been the Chief Operating Officer of Glaukos since 2017. There are 5 older and 5 younger executives at Glaukos. The oldest executive at Glaukos Corporation is William Link, 74, who is the Independent Chairman of the Board.
What's Chris Calcaterra's mailing address?
Chris's mailing address filed with the SEC is C/O GLAUKOS CORPORATION,, 229 AVENIDA FABRICANTE, SAN CLEMENTE, CA, 92672.
Insiders trading at Glaukos
Over the last 11 years, insiders at Glaukos have traded over $300,254,118 worth of Glaukos stock and bought 17,376 units worth $317,262 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Gilbert H Kliman et Jonathan Silverstein. On average, Glaukos executives and independent directors trade stock every 25 days with the average trade being worth of $8,240,079. The most recent stock trade was executed by Gilbert H Kliman on 9 September 2024, trading 3,000 units of GKOS stock currently worth $96,000.
What does Glaukos do?
glaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde
What does Glaukos's logo look like?
Complete history of Mr. Calcaterra stock trades at Glaukos
Glaukos executives and stock owners
Glaukos executives and other stock owners filed with the SEC include:
-
Thomas Burns,
President, Chief Executive Officer, Director -
Chris Calcaterra,
Chief Operating Officer -
Joseph Gilliam,
Chief Financial Officer, Senior Vice President - Corporate Development -
Thomas William Burns,
Chairman, CEO & Pres -
Joseph E. Gilliam,
CFO & Sr. VP of Corp. Devel. -
Chris M. Calcaterra,
Chief Operating Officer -
William Link,
Independent Chairman of the Board -
Marc Stapley,
Independent Director -
Mark Foley,
Independent Director -
Aimee Weisner,
Independent Director -
David Hoffmeister,
Independent Director -
Gilbert Kliman,
Director -
L. Jay Katz,
Chief Medical Officer -
L. Jay Katz M.D., FACS,
Chief Medical Officer -
David S. Haffner,
Sr. VP of New Technologies -
Michele M. Allegretto,
Sr. VP of HR -
Diana A. Scherer,
VP of Compliance & Deputy Gen. Counsel -
Diane W. Biagianti,
Sr. VP & Gen. Counsel -
Christopher William Lewis,
Director of Investor Relations, Corp. Strategy & Devel. -
Dr. Mory Gharib Ph.D.,
Co-Founder -
Advisors Llc Orbi Med Capit...,
-
Advisors Llc Orbi Med Capit...,
-
Equity Partners Iv Lp Montr...,
-
Jonathan Silverstein,
Director -
Richard L Harrison,
Treasurer, CFO & Secretary -
Ventures I Llclubash Barbar...,
-
Ventures I Llcversant Ventu...,
-
Partners Iv Lpblair James C...,
-
Iv Associates Lpblair James...,
-
Viii Associates, L.P.Blair ...,
-
Management Partners Ix, Llc...,
-
Healthcare V, Lpfhm V, Llc ...,
-
Ventures I Llcversant Ventu...,
-
Robert J More,
Director -
Paul S Madera,
Director -
Olav Bergheim,
Director -
Ventures I Llcversant Ventu...,
-
Partners Viii, L.P.Blair Ja...,
-
Capital Associates Iii L.L....,
-
Alex R. Thurman,
SVP & CHIEF FINANCIAL OFFICER -
Tomas Navratil,
CHIEF DEVELOPMENT OFFICER -
Leana Wen,
-
Denice Torres,